Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

PHARMEVIDENCE : revenue, balance sheet and financial ratios

PHARMEVIDENCE is a French company founded 7 years ago, specialized in the sector Intermédiaires spécialisés dans le commerce d'autres produits spécifiques. Based in LYON (69009), this company of category PME shows in 2022 a net income positive of 148 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - PHARMEVIDENCE (SIREN 843082934)
Indicator 2022 2021
Revenue N/C N/C
Net income 148 405 € -27 032 €
EBITDA N/C N/C
Net margin N/C N/C

Revenue and income statement

In 2022, PHARMEVIDENCE generates positive net income of 148 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.

Net income (2022) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

148 405 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at -633%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches -6%. Low autonomy: the company heavily depends on external financing (banks, suppliers).

Debt ratio (2022) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

-633.074%

Financial autonomy (2022) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

-5.583%

Asset age ratio (2022) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

22.2%

Solvency indicators evolution
PHARMEVIDENCE

Sector positioning

Debt ratio
-633.07 2022
2021
2022
Q1: 0.0
Med: 8.65
Q3: 51.36
Excellent -6 pts over 2 years

In 2022, the debt ratio of PHARMEVIDENCE (-633.07) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.

Financial autonomy
-5.58% 2022
2021
2022
Q1: 12.39%
Med: 37.81%
Q3: 62.69%
Watch

In 2022, the financial autonomy of PHARMEVIDENCE (-5.6%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 124.84. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2022) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

124.839

Liquidity indicators evolution
PHARMEVIDENCE

Sector positioning

Liquidity ratio
124.84 2022
2021
2022
Q1: 131.96
Med: 226.37
Q3: 410.84
Watch

In 2022, the liquidity ratio of PHARMEVIDENCE (124.84) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.

Positioning of PHARMEVIDENCE in its sector

Comparison with sector Intermédiaires spécialisés dans le commerce d'autres produits spécifiques

Valuation estimate

Based on 50 transactions of similar company sales (all years), the value of PHARMEVIDENCE is estimated at 238 091 € (range 166 013€ - 817 225€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.

Estimated enterprise value 2022
50 tx
166k€ 238k€ 817k€
238 091 € Range: 166 013€ - 817 225€
NAF 5 all-time

Valuation method used

Net Income Multiple
148 405 € × 1.6x = 238 092 €
Range: 166 013€ - 817 225€

Only this financial indicator is available for this company.

How is this estimate calculated?

This estimate is based on the analysis of 50 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Intermédiaires spécialisés dans le commerce d'autres produits spécifiques)

Compare PHARMEVIDENCE with other companies in the same sector:

Voir toutes les statistiques du secteur Intermédiaires spécialisés dans le commerce d'autres produits spécifiques

Frequently asked questions about PHARMEVIDENCE

What is the revenue of PHARMEVIDENCE ?

The revenue of PHARMEVIDENCE is not publicly disclosed (confidential accounts filed with INPI).

Is PHARMEVIDENCE profitable?

Yes, PHARMEVIDENCE generated a net profit of 148 k€ in 2022.

Where is the headquarters of PHARMEVIDENCE ?

The headquarters of PHARMEVIDENCE is located in LYON (69009), in the department Rhone.

Where to find the tax return of PHARMEVIDENCE ?

The tax return of PHARMEVIDENCE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does PHARMEVIDENCE operate?

PHARMEVIDENCE operates in the sector Intermédiaires spécialisés dans le commerce d'autres produits spécifiques (NAF code 46.18Z). See the 'Sector positioning' section above to compare the company with its competitors.